Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program for Ruxolitinib Cream in Atopic Dermatitis 12/28/2018 Medications, WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 20, 2018-- Incyte (Nasdaq:INCY) today announced that the first patient has been...
Surgeon General: Federal drug classification needs changes 12/06/2018 Medications, The nation's drug classification system should be revisited but illegal drugs shouldn't simply be decriminalized...
Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis 12/04/2018 Medications, CAMBRIDGE, Mass., Dec. 2, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in...
Pain common and increasing in prevalence in New Zealand 12/01/2018 Medications, Pain is an extremely common condition and increasing in prevalence in New Zealand, University of...
An opioid epidemic may be looming in Mexico—and the US may be partly responsible 11/29/2018 Medications, Though opioid use in Mexico has been low, national and international factors are converging and...
FDA Grants Orphan Drug Designation To RGX-181 Gene Therapy For The Treatment Of CLN2 Form Of Batten Disease 11/19/2018 Medications, ROCKVILLE, Md., Nov. 14, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology...
Isofol Announces Initiation of a Pivotal Phase 3 Clinical Trial of arfolitixorin for the Treatment of Metastatic Colorectal Cancer 11/19/2018 Medications, GOTHENBURG, Sweden, November 15, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL)...
Will My Insurance Pay For GoodRx? It's Worth A Try – Here's Why. 11/15/2018 Medications, Nearly half of Americans now have high-deductible health plans (HDHPs), which means they’re...
Study examines opioid use among Massachusetts adolescents, trends in opioid prescriptions 11/13/2018 Medications, Opioid-related overdoses and deaths remain a major public health concern in Massachusetts, yet adolescents who...
Phase III Trial of Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint 11/08/2018 Medications, WHIPPANY, N.J., Oct. 24, 2018 /PRNewswire/ -- The Phase III ARAMIS (Androgen Receptor inhibiting Agent...